12:00 AM
 | 
Dec 10, 2012
 |  BioCentury  |  Emerging Company Profile

Xenikos: Dual attack in GvHD

Xenikos' T-Guard targeting CD3, CD7 for graft-versus-host disease

Xenikos B.V.'s T-Guard, a mAb-toxin fusion protein that blocks activation of T cells associated with graft-versus-host disease, is being developed to provide faster symptom relief and better safety than high-dose corticosteroids now used in GvHD patients who have failed first-line treatment.

Graft-versus-host disease occurs when T cells in allogeneic stem cell transplants begin attacking the host's tissues. These T cells activate additional immune system cells such as monocytes and natural killer (NK) T cells, resulting in damage to the epithelial cells of the skin, liver and gut.

The most severe form of acute GvHD is associated with five-year survival rates as low as 5%.

About half of transplant patients develop acute GvHD and receive first-line therapy with corticosteroids. The drugs only work about half the time, and second-line therapy for the non-responders is steroid doses that are up to 10 times higher than in the first-line setting. This can lead to safety issues such as infections and mortality.

T-Guard was...

Read the full 785 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >